Hematology News

SAN DIEGO — Red blood cell transfusion did not increase risk for thrombotic events in adjusted analyses, despite reports of increased risk in previous observational studies, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A procedure for interrupting direct oral anticoagulant therapy in the perioperative setting conferred low rates of bleeding among both low-risk and high-risk patients with atrial fibrillation, according to findings from the prospective PAUSE study presented during the late-breaking abstract session at ASH Annual Meeting and Exposition.

SAN DIEGO — Patients with severe hemophilia A achieved factor VIII activity levels sufficient to reduce or prevent spontaneous hemorrhage after a single IV infusion of AAV8-HLP-hFVIII-V3, according to results of a phase 1/phase 2, open-label, nonrandomized dose-escalation trial presented at ASH Annual Meeting and Exposition.

SAN DIEGO — An inexpensive, easy-to-use diagnostic tool for sickle cell disease showed 100% accuracy among a large cohort of children from Uganda, according to findings presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.

SAN DIEGO — Rivaroxaban prophylaxis significantly reduced thromboembolic events among patients receiving systemic cancer therapy, according to findings of a double-blind, randomized, placebo-controlled study presented at the late-breaking abstract session of ASH Annual Meeting and Exposition.

An increase in the absolute neutrophil count/absolute lymphocyte count ratio may indicate increased risk for VTE in patients with diffuse large B-cell lymphoma, according to findings presented at the ASH Annual Meeting and Exposition.

Following the positive results of the HOPE Study at ASH Annual Meeting and Exposition, Global Blood Therapeutics announced it will submit a new drug application to the FDA for voxelotor through an accelerated approval pathway, according to a press release issued by the company.

SAN DIEGO — The anti-interferon-gamma therapy emapalumab conferred an overall response rate of more than 60% in a cohort of young children with primary hemophagocytic lymphohistiocytosis, according to results of an international, multicenter, open-label, single-arm, phase 2/phase 3 study presented during the late-breaking abstract session at ASH Annual Meeting and Exposition.

SAN DIEGO — ASH honored three practitioners as Choosing Wisely champions at ASH Annual Meeting and Exhibition for successfully implementing programs at their institutions that reduced the use of unneeded hematology tests and treatments.

SAN DIEGO — Patients with cancer-associated venous thromboembolism treated with oral apixaban appeared significantly less likely to experience VTE recurrence than those who received parenteral dalteparin, according to study results presented at ASH Annual Meeting and Exposition.